LENZ Therapeutics Announces Completion of Merger with Graphite Bio

LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, has announced the completion of its previously announced merger with Graphite Bio, Inc. (previously trading on Nasdaq under the ticker symbol “GRPH”) (“Graphite Bio”). The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024.

Read the full article: LENZ Therapeutics Announces Completion of Merger with Graphite Bio //

Source: https://www.businesswire.com/news/home/20240321281097/en/LENZ-Therapeutics-Announces-Completion-of-Merger-with-Graphite-Bio-and-Provides-Update-on-Recent-Clinical-and-Corporate-Progress

Leave a Comment

Your email address will not be published.

Scroll to Top